Advertisement
YOU ARE HERE: LAT HomeCollectionsUnited States Foreign Investments Yugoslavia
IN THE NEWS

United States Foreign Investments Yugoslavia

FEATURED ARTICLES
BUSINESS
February 13, 1999 | Bloomberg News
Milan Panic, chairman of ICN Pharmaceuticals Inc., appealed to President Clinton on Friday to condemn the "wholly illegal" seizing of the company's Belgrade factory by the Yugoslavian government. In an open letter published in the New York Times, Panic claimed the government had no right to seize the plant, and he urged Clinton to demand that the factory be returned to the 11313775246, accusing ICN of not abiding by its 1991 purchase agreement.
ARTICLES BY DATE
BUSINESS
March 5, 1999 | From Times Staff and Wire Reports
ICN Pharmaceuticals Inc. posted a fourth-quarter loss of $218 million, or $2.85 a share, as it wrote off a key Yugoslavian plant seized last month by Serbian troops. The Costa Mesa-based drug maker took a charge of $230 million in the quarter, the latest in a series of charges related to economic and political instability in Yugoslavia and other parts of Eastern Europe.
Advertisement
BUSINESS
April 30, 1992
Yugoslav health officials have given approval for SPI Pharmaceutical Inc.'s Belgrade subsidiary to market its patented antiviral drug, Virazole, for injection treatment of a deadly fever, the company said Wednesday. Yugoslavia is the first European nation to authorize use of Virazole to treat hemorrhagic fever associated with Renal Syndrome. The disease is characterized by severe shock, internal bleeding and kidney failure and is caused by the Hantaan virus.
BUSINESS
February 13, 1999 | Bloomberg News
Milan Panic, chairman of ICN Pharmaceuticals Inc., appealed to President Clinton on Friday to condemn the "wholly illegal" seizing of the company's Belgrade factory by the Yugoslavian government. In an open letter published in the New York Times, Panic claimed the government had no right to seize the plant, and he urged Clinton to demand that the factory be returned to the 11313775246, accusing ICN of not abiding by its 1991 purchase agreement.
BUSINESS
October 3, 1990 | Cristina Lee / Times staff writer
The Keith Cos., a private engineering and planning firm in Costa Mesa, said it has teamed up with a Yugoslav company to bid for major international construction projects. Centroprojekt, the Yugoslav company, is one of that country's largest architectural and engineering firms. Currently, the two companies are working together to bid for three hotel projects in Yugoslavia with a combined value of $75 million, said Larry Mandell, Keith senior vice president.
BUSINESS
February 9, 1999 | PAUL WATSON, TIMES STAFF WRITER
More than 1,000 ICN Pharmaceuticals Inc. workers walked off the job in Yugoslavia on Monday to support their boss, Milan Panic, in his fight to take back a factory seized by the Yugoslav government. But police here turned the screws still tighter on ICN's Yugoslav subsidiary by arresting six of his local vice presidents, Panic said. "I think this is not about business anymore," Panic, chairman and chief executive of the Costa Mesa-based company, said in a telephone interview Monday from Hungary.
BUSINESS
March 5, 1999 | From Times Staff and Wire Reports
ICN Pharmaceuticals Inc. posted a fourth-quarter loss of $218 million, or $2.85 a share, as it wrote off a key Yugoslavian plant seized last month by Serbian troops. The Costa Mesa-based drug maker took a charge of $230 million in the quarter, the latest in a series of charges related to economic and political instability in Yugoslavia and other parts of Eastern Europe.
BUSINESS
March 28, 1990 | CRISTINA LEE, TIMES STAFF WRITER
SPI Pharmaceuticals Inc.'s planned merger with Yugoslavia's second-largest drug maker, Galenika, is on track, SPI's chairman said Tuesday, but ironing out details of the deal will take another three to six months. The acquisition, announced in February, is expected to cost SPI between $50 million and $100 million, including the expected cost of renovating Galenika's pharmaceutical plants in Yugoslavia, SPI Chairman Milan Panic said.
BUSINESS
November 24, 1990 | CRISTINA LEE, TIMES STAFF WRITER
SPI Pharmaceuticals Inc. has signed a definitive agreement to merge with Yugoslavia's largest drug and chemical manufacturer and will form a new company that is expected to have expected annual sales of $370 million. Under the agreement announced Thursday, the assets of Belgrade-based Galenika Pharmaceuticals would be transferred to a new joint-venture company, ICN Galenika Inc., to be based in Costa Mesa.
BUSINESS
November 24, 1990 | CRISTINA LEE, TIMES STAFF WRITER
SPI Pharmaceuticals Inc. of Costa Mesa has completed its merger with Yugoslavia's largest drug and chemical manufacturer and will form a new company that will have expected annual sales of $370 million. Under the agreement announced Thursday, the assets of Belgrade-based Galenika Pharmaceuticals would be transferred to a new joint venture company, ICN Galenika Inc., to be based in Costa Mesa.
BUSINESS
February 9, 1999 | PAUL WATSON, TIMES STAFF WRITER
More than 1,000 ICN Pharmaceuticals Inc. workers walked off the job in Yugoslavia on Monday to support their boss, Milan Panic, in his fight to take back a factory seized by the Yugoslav government. But police here turned the screws still tighter on ICN's Yugoslav subsidiary by arresting six of his local vice presidents, Panic said. "I think this is not about business anymore," Panic, chairman and chief executive of the Costa Mesa-based company, said in a telephone interview Monday from Hungary.
BUSINESS
April 30, 1992
Yugoslav health officials have given approval for SPI Pharmaceutical Inc.'s Belgrade subsidiary to market its patented antiviral drug, Virazole, for injection treatment of a deadly fever, the company said Wednesday. Yugoslavia is the first European nation to authorize use of Virazole to treat hemorrhagic fever associated with Renal Syndrome. The disease is characterized by severe shock, internal bleeding and kidney failure and is caused by the Hantaan virus.
BUSINESS
November 28, 1990 | LESLIE BERKMAN, TIMES STAFF WRITER
By reaching from Orange County to Belgrade, SPI Pharmaceuticals Inc. is in the vanguard of U.S. pharmaceutical companies seeking to exploit new business opportunities in Eastern Europe. SPI, a small Costa Mesa drug distributor, last week signed a definitive agreement to form a new joint-venture company with Galenika Pharmaceuticals, Yugoslavia's largest drug and chemical manufacturer.
BUSINESS
November 24, 1990 | CRISTINA LEE, TIMES STAFF WRITER
SPI Pharmaceuticals Inc. has signed a definitive agreement to merge with Yugoslavia's largest drug and chemical manufacturer and will form a new company that is expected to have expected annual sales of $370 million. Under the agreement announced Thursday, the assets of Belgrade-based Galenika Pharmaceuticals would be transferred to a new joint-venture company, ICN Galenika Inc., to be based in Costa Mesa.
BUSINESS
November 24, 1990 | CRISTINA LEE, TIMES STAFF WRITER
SPI Pharmaceuticals Inc. of Costa Mesa has completed its merger with Yugoslavia's largest drug and chemical manufacturer and will form a new company that will have expected annual sales of $370 million. Under the agreement announced Thursday, the assets of Belgrade-based Galenika Pharmaceuticals would be transferred to a new joint venture company, ICN Galenika Inc., to be based in Costa Mesa.
BUSINESS
October 3, 1990 | Cristina Lee / Times staff writer
The Keith Cos., a private engineering and planning firm in Costa Mesa, said it has teamed up with a Yugoslav company to bid for major international construction projects. Centroprojekt, the Yugoslav company, is one of that country's largest architectural and engineering firms. Currently, the two companies are working together to bid for three hotel projects in Yugoslavia with a combined value of $75 million, said Larry Mandell, Keith senior vice president.
BUSINESS
November 28, 1990 | LESLIE BERKMAN, TIMES STAFF WRITER
By reaching from Orange County to Belgrade, SPI Pharmaceuticals Inc. is in the vanguard of U.S. pharmaceutical companies seeking to exploit new business opportunities in Eastern Europe. SPI, a small Costa Mesa drug distributor, last week signed a definitive agreement to form a new joint-venture company with Galenika Pharmaceuticals, Yugoslavia's largest drug and chemical manufacturer.
BUSINESS
March 28, 1990 | CRISTINA LEE, TIMES STAFF WRITER
SPI Pharmaceuticals Inc.'s planned merger with Yugoslavia's second-largest drug maker, Galenika, is on track, SPI's chairman said Tuesday, but ironing out details of the deal will take another three to six months. The acquisition, announced in February, is expected to cost SPI between $50 million and $100 million, including the expected cost of renovating Galenika's pharmaceutical plants in Yugoslavia, SPI Chairman Milan Panic said.
Los Angeles Times Articles
|